癌药新资- 安健肿瘤治疗中心癌药新资简介
近年，有不少治癌新药物涌现，并带来革命性的治疗效果。这些新的药物包括化疗丶其他生物制剂和个别癌症的标靶治疗。这些药物不单只增强个别癌症的治疗效用，而且副作用较少。为了病人的利益，本诊所致力为病人在本港或海外寻找最新且有效的药物。
(最新更新日期：2016年8月1日)
主治癌症 / 治療範圍 |
FDA 認可年份 |
藥名 |
|||
|
Lung Cancer 肺癌 |
|||||
|
EGFR T790M mutation positive |
2015 |
Osimertinib (Tagrisso) 塔格瑞斯 |
|||
|
Lung Cancer (肺癌) |
2015 |
Penbrolizumab (Keytruda) 健痊得 |
|||
|
Squamous cell lung cancer (扁平上皮細胞肺癌) |
2015 |
Necitumumab (Portrazza) |
|||
|
Lung Cancer + ALK |
2015 |
Alectinib (Alecensa) 鹽酸阿雷替尼 |
|||
|
Squamous cell lung cancer (扁平上皮細胞肺癌) |
2015 |
Opdivo (Nivolumab) |
|||
|
ALK + Non small cell Lung cancer (ALK + 非小细胞肺癌) |
2014 |
Zykadia (ceritinib) |
|||
|
EGFR mutation + lung cancer (表皮生長因子受體+ 肺癌) |
2013 |
Gilotrif (afatinib) |
|||
|
Lung Cancer (肺癌) |
2012 |
Abraxane (paclitaxel protein-bound) |
|||
|
ALK + Non small cell Lung cancer (ALK + 非小细胞肺癌) |
2011 |
Xalkori (crizotinib) |
|||
|
Colorectal Cancer 結直腸癌 |
|||||
|
Colorectal Cancer (結直腸癌) |
2015 |
1) Ramucirumab (Cyramza) 雷莫蘆單抗 |
|||
|
Colorectal Cancer (結直腸癌) |
2012 |
1) Zaltrap (ziv-aflibercept) |
|||
|
Breast Cancer 乳癌 |
|||||
|
ER +, HER 2 – Breast Cancer (ER +, Her 2 - 乳癌) |
2015 |
Ibrance (palbociclib) |
|||
|
HER 2+ Breast Cancer (Her 2 + 乳癌) |
2013 |
Kadcyla (ado-trastuzumab emtansine) |
|||
|
HER 2+ Breast Cancer (Her 2 + 乳癌) |
2012 |
Perjeta (petuzumab) |
|||
|
Hormone receptor + Breast Cancer (激素受體 + 乳癌) |
2012 |
Afinitor (everolimus) |
|||
|
Breast Cancer (乳癌) |
2010 |
Halaven (eribulin mesylate) |
|||
|
Prostate Cancer 前列腺癌 |
|||||
|
Castration resistant Prostate Cancer |
2012 |
Xtandi (enzalutamide) |
|||
|
Prostate Cancer (前列腺癌) |
2011 |
Zytiga (abiraterone acetate) |
|||
|
Hormone refractory Prostate Cancer (激素非依賴性前列腺癌) |
2010 |
Provenge (sipuleucel-T) |
|||
|
Prostate Cancer (前列腺癌) |
2010 |
Jevtana (cabazitaxel) |
|||
|
Malignant Melanoma皮膚惡性黑色素瘤 |
|||||
|
BRAF mutation positive |
2015 |
Cobimetinib (Cotellic) |
|||
|
Melanoma (皮膚黑色素瘤) |
2014 |
1) Keytruda (pembrolizumab) |
|||
|
Stomach Cancer 胃癌 |
2014 |
Cyramza (ramucirumab) |
|||
|
BRAF + Melanoma (BRAF + 皮膚黑色素瘤) |
2013 |
1) Tafinlar (dabrafenib) |
|||
|
BRAF + Melanoma (BRAF + 皮膚黑色素瘤) |
2011 |
Zelboraf (vemurafenib) |
|||
|
Melanoma (皮膚黑色素瘤) |
2011 |
Yervoy (ipilimumab) |
|||
|
Malignant Lymphoma 惡性淋巴瘤 |
|||||
| Hodgkin’s lymphoma (何傑金氏淋巴瘤) | 2016 (5月) | Opdivo (Nivolumab) (最新) | |||
|
Lymphoma Waldenstrom’s Macroglobulinemia |
2015 |
Ibrutinib (Imbruvica) 依魯替尼 |
|||
|
Follicular B cell Lymphoma (濾泡性淋巴瘤)/ |
2014 |
Zydelig (idelalisib) |
|||
|
Peripheral T cell Lymphoma (外周T细胞淋巴瘤) |
2014 |
Beleodaq (belinostat) |
|||
|
Mantle Cell Lymphoma (套細胞淋巴瘤) |
2013 |
1) Revlimid (lenalidomide) |
|||
|
Hodgkin’s lymphoma (何傑金氏淋巴瘤) / |
2011 |
Adcetris (brentuximab vendotin) |
|||
|
Kidney Cancer 腎癌 |
|||||
| Kidney Cancer (腎癌) | 2016 (5月) 2016 (4月) |
Levima (Lenvatinib) (最新) Cabometyx (Cabozantinib) (最新) |
|||
|
Kidney Renal Cell cancer (腎癌) |
2015 |
Nivolumab (Opdivo) 尼魯單抗 |
|||
|
Kidney Cancer 腎癌 |
2012 |
Inlyta (Axitinib) |
|||
|
Bladder Cancer膀胱癌 |
|||||
|
Bladder Cancer (膀胱癌) |
2016 (5月) |
Tecentriq (Otezolizumab) (最新) |
|||
|
Skin Cancer 皮膚癌 |
|||||
|
Basal cell Carcinoma (基底细胞癌) |
2012 |
Erivedge (vismodegib) |
|||
|
Pancreas Cancer 胰臟癌 |
|||||
|
Pancreas Cancer (胰臟癌) |
2015 |
Irinotecan Liposome Inj. (Onivyde) |
|||
|
Acute Leukemia急性白血病 |
|||||
|
Acute Lymphocytic Leukemia |
2014 |
Blincyto (blinatumomab) |
|||
|
Acute Lymphocytic Leukemia |
2012 |
Marqibo (vinCRIStine sulfate LIPOSOME injection) |
|||
|
Chronic Leukemia 慢性白血病 |
|||||
| Chronic Lymphocytic Leukemia 慢性淋巴性白血病 | 2016 (4月) | Venclexta (Venetoclax) (最新) | |||
|
Chronic Lymphocytic Leukemia, Follicular B cell lymphoma, small lymphocytic lymphoma |
2014 |
Zydelig (idelalisib) |
|||
|
Chronic lymphocytic Leukemia |
2014 |
Imbruvica (ibrutinib) |
|||
|
Chronic lymphocytic Leukemia |
2013 |
Gazyva (oblintuzumab) |
|||
|
Chronic Myeloid Leukemia |
2012 |
Bosulif (bosutinib) |
|||
|
Chronic Myeloid Leukemia |
2012 |
Iclusig (ponatinib) |
|||
|
Chronic Myeloid Leukemia |
2012 |
Synribo (omacetaxine mepesuccinate) |
|||
|
Multiple Myeloma 多發性骨髓瘤 |
|||||
|
Multiple Myeloma |
2015 |
1) Elotuzumab (Empliciti)埃羅妥珠單抗 |
|||
|
Multiple Myeloma |
2013 |
1) Pomalyst (pomalidomide) |
|||
|
Multiple Myeloma |
2012 |
Kyprolis (carfizomib) |
|||
|
Ovary Cancer 卵巢癌 |
|||||
|
BRCA mutated Ovary Cancer |
2014 |
Lynparza (olaparib) |
|||
|
Thyroid Cancer甲狀腺癌 |
|||||
|
Thyroid Cancer (甲狀腺癌) |
2015 |
Lenvatinib (Lenvima) 樂伐替尼 |
|||
|
Medullary thyroid cancer (甲状腺髓样癌) |
2012 |
Cometriq (cabozantinib) |
|||
|
Thyroid Cancer (甲狀腺癌) |
2011 |
Vandetanib (vandetanib) |
|||
|
Sarcoma肉瘤 |
|||||
|
Soft Tissue Sarcoma (軟組織肉瘤) |
2015 |
Trabectedin (Yondelis) 曲貝替定 |
|||
|
Soft Tissue Sarcoma (軟組織肉瘤) |
2012 |
Votrient (pazopanib) |
|||
|
Neuroendocrine Tumor神經內分泌腫瘤 |
|||||
|
Pancreatic Neuroendocrine Tumor |
2011 |
Afinitor (everolimus) |
|||
|
Neuroblastoma神經母細胞瘤 |
|||||
|
Neuroblastoma神經母細胞瘤 |
2015 (3月) |
Unituxin (Dinutuximab) (最新) |
|||
|
Basal Cell Carcinoma 基底細胞癌 |
|||||
|
Basal Cell Carcinoma 基底細胞癌 |
2015 (7月) |
Odomzo (Sonidegib) (最新) |
|||
